No connection

Search Results

IMTX vs WVE

IMTX
Immatics N.V.
BEARISH
Price
$10.43
Market Cap
$1.4B
Sector
Healthcare
AI Confidence
85%
WVE
Wave Life Sciences Ltd.
BEARISH
Price
$7.31
Market Cap
$1.38B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
IMTX
--
WVE
--
Forward P/E
IMTX
-5.91
WVE
-5.46
P/B Ratio
IMTX
2.5
WVE
2.65
P/S Ratio
IMTX
28.98
WVE
32.21
EV/EBITDA
IMTX
-5.47
WVE
-3.77

Profitability

Gross Margin
IMTX
-280.87%
WVE
0.0%
Operating Margin
IMTX
-196.76%
WVE
-327.44%
Profit Margin
IMTX
0.0%
WVE
0.0%
ROE
IMTX
-37.1%
WVE
-54.97%
ROA
IMTX
-18.08%
WVE
-27.18%

Growth

Revenue Growth
IMTX
-64.9%
WVE
-79.4%
Earnings Growth
IMTX
--
WVE
--

Financial Health

Debt/Equity
IMTX
0.03
WVE
0.03
Current Ratio
IMTX
11.72
WVE
6.47
Quick Ratio
IMTX
11.07
WVE
6.35

Dividends

Dividend Yield
IMTX
--
WVE
--
Payout Ratio
IMTX
0.0%
WVE
0.0%

AI Verdict

IMTX BEARISH

IMTX exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health and operational efficiency. While the company maintains an exceptionally strong liquidity position (Current Ratio of 11.72) and low debt, these are overshadowed by a catastrophic 64.90% year-over-year decline in revenue and deeply negative gross margins (-280.87%). The stock currently trades at a speculative premium with a Price/Sales ratio of 28.98 despite shrinking top-line growth. Any potential upside is driven by analyst price targets ($18.75) rather than current financial performance.

Strengths
Exceptional short-term liquidity with a Current Ratio of 11.72
Very low leverage with a Debt/Equity ratio of 0.03
Significant analyst price target upside (Target: $18.75 vs Price: $10.43)
Risks
Severe revenue contraction (-64.90% YoY)
Extreme operational inefficiency with Gross Margins at -280.87%
Critical Piotroski F-Score (1/9) signaling fundamental decay
WVE BEARISH

WVE exhibits severe financial distress from a deterministic standpoint, highlighted by a critical Piotroski F-Score of 1/9. While the company maintains a strong liquidity position with a current ratio of 6.47 and negligible debt, these are offset by a catastrophic 79.4% decline in year-over-year revenue and an operating margin of -327.44%. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish reality of insider selling by the CEO and CFO, alongside a recent 37% price collapse. The valuation is purely speculative, as evidenced by a Price/Sales ratio of 32.21 in the face of shrinking revenues.

Strengths
Very low Debt/Equity ratio (0.03)
Strong short-term liquidity (Current Ratio 6.47)
High analyst target price ($24.93) suggesting potential clinical catalysts
Risks
Severe revenue contraction (-79.4% YoY)
Extreme operational inefficiency (Operating Margin -327.44%)
Consistent failure to meet earnings estimates (0/4 beats in last 4 quarters)

Compare Another Pair

IMTX vs WVE: Head-to-Head Comparison

This page compares Immatics N.V. (IMTX) and Wave Life Sciences Ltd. (WVE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile